Drew Carleton
United States
Dr. Eugene Bauer serves as Board Member at First Crush Automated Pill Crusher. He serves as Clinical and Scientific Advisor at Alladapt Immunotherapeutics. He is also a Co-Founder, Chief Medical Officer and Board Member at Dermira. He also is a Co-Founder and serves as Chief Medical Officer & Board Member at Evommune. He served as a Board Member at Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.),He serves as Board member at First Crush Automated Pill Crusher. Prior to founding Dermira, he served as a member of Peplin's board of directors and its President and Chief Medical Officer, until its acquisition by LEO Pharma. He was also the Chief Executive Officer of Neosil Inc. and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, he served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. He is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002. Gene has served on the boards of directors of a number of public and private companies. He is currently a member of the boards of directors of First Wave Technologies, Inc., Cerecor, Inc. and Kadmon Corporation. He previously served as a member of the boards of directors of Dr. Tattoff, Inc., Protalex, Inc., Vyteris, Inc., Peplin, PetDRx, Inc., Arbor Vita Corp., Patient Safety Technologies, Inc., MediSync Bioservices and Modigene Inc. (renamed PROLOR Biotech, Inc.). Gene was a U.S. National Institutes of Health (NIH)-funded investigator for 25 years and has served on review groups for the NIH. He has been elected to several societies, including the National Academy of Medicine of the United States and currently serves as a director of the American Dermatological Association, Inc. Gene received a B.S. in medicine and an M.D. from Northwestern University.
Individual/Angel